Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Under Scrutiny: Congress Presses Agency On Antidepressants, Plan B

Executive Summary

Congress is asking FDA to document its actions in two high-profile agency decisions

Related Content

FDA Drug Safety Office Is “Separate, But Unequal,” Senate Committee Says
FDA Handling Of Antidepressant Inquiry “Troubles” Senate Investigators
FDA Advisory Cmte. Members Should Be Vetted For Opinions, GAO Says
Plan B “Not Approvable” Decision Puts FDA, CDER Director In Hot Seat
House Committee Watching Genasense; Show Of Force During FDA Review
FDA Responds To Antidepressant Inquiry, Says All Data Properly Disclosed
FDA Requests Antidepressant Labeling Add Suicidality Warning
FDA Requests Antidepressant Labeling Add Suicidality Warning
FDA Action On Antidepressants Questioned; Congress Widens Investigation
Antidepressant Warnings On Pediatric Suicide Need Immediate Strengthening



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts